A team of scientists at a unit of China National Biotech Group (CNBG) has developed a potential treatment for COVID-19 infection using blood plasma taken from convalescents, reported Yicai Global.
Beijing Tiantan Biological Products, which controls Wuhan Blood Products, one of the main collaborators on the project, closed 10% higher on the news.
The new therapy has had "markedly good results" in the treatment of over 10 critically ill patients, CNBG said.
Within 12 to 24 hours of treatment, inflammation levels dropped, lymphocyte count rose and symptoms were alleviated, the Beijing-based firm added.
China's National Health Commission supported the use of convalescent plasma therapy in a document released on February 5, while authorities in Wuhan, the city at the epicenter of the outbreak, are calling on recovered patients to donate their plasma.
CNBG has been collecting plasma from convalescent patients in Wuhan since January 20, the news source said.
To read more NewsPoints articles, click here.